- Home
- EQX vs BMRN Comparison
EQX vs BMRN Comparison
Compare EQX & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- BMRN
- Stock Information
- Founded
- EQX 2007
- BMRN 1996
- Country
- EQX Canada
- BMRN United States
- Employees
- EQX N/A
- BMRN N/A
- Industry
- EQX Precious Metals
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- EQX Basic Materials
- BMRN Health Care
- Exchange
- EQX Nasdaq
- BMRN Nasdaq
- Market Cap
- EQX 8.4B
- BMRN 10.0B
- IPO Year
- EQX N/A
- BMRN 1999
- Fundamental
- Price
- EQX $10.97
- BMRN $53.57
- Analyst Decision
- EQX Buy
- BMRN Buy
- Analyst Count
- EQX 1
- BMRN 18
- Target Price
- EQX $17.00
- BMRN $91.06
- AVG Volume (30 Days)
- EQX 13.9M
- BMRN 2.8M
- Earning Date
- EQX 11-05-2025
- BMRN 10-27-2025
- Dividend Yield
- EQX N/A
- BMRN N/A
- EPS Growth
- EQX N/A
- BMRN 59.53
- EPS
- EQX N/A
- BMRN 2.68
- Revenue
- EQX $1,905,732,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- EQX $65.90
- BMRN $13.35
- Revenue Next Year
- EQX $49.28
- BMRN $9.18
- P/E Ratio
- EQX N/A
- BMRN $19.98
- Revenue Growth
- EQX 74.31
- BMRN 12.39
- 52 Week Low
- EQX $4.95
- BMRN $51.00
- 52 Week High
- EQX $12.93
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- EQX 49.56
- BMRN 49.21
- Support Level
- EQX $10.24
- BMRN $52.26
- Resistance Level
- EQX $11.31
- BMRN $56.80
- Average True Range (ATR)
- EQX 0.44
- BMRN 1.79
- MACD
- EQX -0.19
- BMRN 0.02
- Stochastic Oscillator
- EQX 27.14
- BMRN 44.12
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.